OncoMatch/Clinical Trials/NCT07200102
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Is NCT07200102 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Selinexor for multiple myeloma.
Treatment: Selinexor — The outcomes in patients with relapsed multiple myeloma refractory to triple-therapy (anti-CD38, immunomodulatory drugs (IMiD) and proteasome inhibitors (PI)) remain poor. These patients are eligible for chimeric antigen receptor T-cells (CAR-T), which rely on redirecting autologous T-cells to clear myeloma cells by targeting B-cell maturation antigen (BCMA). BCMA CAR-T therapy is not curative, and unlike autologous stem cell transplant, there is currently no standard for maintenance therapy post CAR-T which could potentially increase MRD rates and extend progression-free survival. Selinexor is an exportin (XPO1) inhibitor with direct anti-tumor effect used often as an adjunct with other agents as bridging therapy prior to CAR-T. As selinexor does not affect T-cell yields or fitness, T-cell collection on selinexor for CAR-T manufacturing is safe. The aim of this study is to evaluate the safety and toxicity of selinexor in triple-exposed or refractory multiple myeloma patients with high-risk features (adverse risk cytogenetics, less than complete response (CR) post CAR-T, or extramedullary disease) following BCMA CAR-T therapy. The investigators hypothesize that selinexor as maintenance therapy following CAR-T has the potential to act synergistically with CAR-T cells leading to more durable responses.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: car-t cell therapy (ciltacabtagene autoleucel) — standard of care
Cannot have received: xpo1 inhibitor (selinexor)
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.0 K/cumm; Platelets ≥ 50 K/cumm; Hemoglobin ≥ 8.5 g/dL without blood transfusion within 7 days before C1D1
Kidney function
Calculated creatinine clearance ≥ 15 mL/min by Cockcroft-Gault
Liver function
Total bilirubin ≤ 1.5 x IULN; patients with Gilbert's syndrome must have a total bilirubin < 3 x IULN. AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN
Cardiac function
congestive heart failure of NYHA class ≥ 3 or known left ventricular ejection fraction of < 40%, or myocardial infarction within 3 months prior to CAR-T therapy [excluded]
Adequate bone marrow and organ function at Day 30 post CAR-T (+28 /-14 days) as defined below: Absolute neutrophil count ≥ 1.0 K/cumm; Platelets ≥ 50 K/cumm; Hemoglobin ≥ 8.5 g/dL without blood transfusion within 7 days before C1D1. Total bilirubin ≤ 1.5 x IULN; patients with Gilbert's syndrome must have a total bilirubin < 3 x IULN. AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN. Calculated creatinine clearance ≥ 15 mL/min by Cockcroft-Gault
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07200102 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior xpo1 inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages